Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

China · Delayed Price · Currency is CNY

8.22

-0.12 (-1.44%)

Sep 24, 2026, 3:00 PM CST

Market Cap	11.02B -23.5%
Revenue (ttm)	8.43B -14.5%
Net Income	545.12M -47.4%
EPS	0.41 -47.4%
Shares Out	1.34B
PE Ratio	20.22
Forward PE	n/a
Dividend	0.30 (3.65%)
Ex-Dividend Date	Sep 18, 2026

Volume	5,899,600
Open	8.33
Previous Close	8.34
Day's Range	8.20 - 8.39
52-Week Range	7.67 - 11.09
Beta	0.08
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granule... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1996

Employees 9,697

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600420

Full Company Profile

Financial Performance

In 2025, SHA:600420's revenue was 9.36 billion, a decrease of -14.39% compared to the previous year's 10.94 billion. Earnings were 941.60 million, a decrease of -13.11%.

Financial Statements